Orion Oyj (BIT:1ORNBV)

Market Cap	9.80B +42.2%
Revenue (ttm)	1.95B +22.9%
Net Income	529.40M +52.4%
EPS	3.76 +52.1%
Shares Out	n/a
PE Ratio	18.52
Forward PE	16.11
Dividend	1.80 (2.45%)
Ex-Dividend Date	Oct 19, 2026

Volume	n/a
Average Volume	2
Open	n/a
Previous Close	73.10
Day's Range	n/a
52-Week Range	52.55 - 78.15
Beta	n/a
RSI	51.04
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,132
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ORNBV

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.